logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Late 2017
BioLineRx Ltd.
Topline results from phase II trial of BL-8040
Novel Stem Cell Mobilization Treatment
Late 2017
SCYNEXIS, Inc.
Topline data from phase 2 study of IV/Oral SCY-078
Invasive Candidiasis
Late 2017
CONCERT PHARMACEUTICALS, INC.
Report Phase 2 monotherapy top-line efficacy data of CTP-656
Cystic fibrosis
Late 2017
Ardelyx, Inc
Data read-out from phase 3 study of Tenapanor (T3MPO-2)
irritable bowel syndrome with constipation (IBS-C)
Late 2017
Momenta Pharmaceuticals Inc
Topline data from Phase 1 clinical trial for M834,
Proposed Biosimilar of ORENCIA
Sep 2017
Versartis Inc.
Top-line data from pediatric phase 3 trial of Somavaratan (VELOCITY)
pediatric growth hormone deficiency (GHD)
Late 2017
CONCERT PHARMACEUTICALS, INC.
Topline data from phase 2 trial of CTP-543
alopecia areata
Late 2017
Corcept Therapeutics Inc
Results from phase 2 trial of CORT125134
Cushing's syndrome
Late 2017
Bellerophon Therapeutics LLC
Interim analysis of Phase 3 program for INOpulse (INOvation-1)
Pulmonary Arterial Hypertension
Late 2017
BioLineRx Ltd.
Topline results from Phase 2 allogeneic transplantation study of BL-8040
autologous stem cell mobilization
Late 2017
bluebird bio Inc.
Full data from initial 17 patients in Phase 2/3 study of Lenti-D (Starbeam)
cerebral adrenoleukodystrophy (CALD)
Late 2017
Reata Pharmaceuticals, Inc.
Data from phase 2 portion of Phase 2/3 trial of bardoxolone methyl
patients with chronic kidney disease caused by Alport syndrome
Sep 2017
Ligand Pharmaceuticals Inc
Top line data from phase II trial of LGD-6972
Type 2 diabetes mellitus
Late 2017
CONCERT PHARMACEUTICALS, INC.
Top line data from Phase 2a trial of CTP-543
moderate-to-severe alopecia areata
Late 2017
CONCERT PHARMACEUTICALS, INC.
Top line data from Phase 2 trial of CTP-656 i
Cystic Fibrosis
Late 2017
Regenxbio Inc
Interim results from phase I/II trial of RGX-501
homozygous familial hypercholesterolemia
Late 2017
Bellerophon Therapeutics LLC
Top line results from phase 3 study of INOpulse
Pulmonary Arterial Hypertension
Late 2017
Agios Pharmaceuticals, Inc.
Submit NDA for Ivosidenib
IDH1m positive Relapsed and Refractory Acute Myeloid Leukemia
Late 2017
Otonomy Inc.
Topline data from phase 3 study of OTIVIDEX (AVERTS-2)
Ménière’s disease
Late 2017
AcelRx Pharmaceuticals Inc.
Resubmission of ZALVISO NDA
management of moderate-to-severe acute pain in adult patients in the hospital setting
Late 2017
Pfizer Inc.
Data from phase 3 trial of XTANDI (PROSPER)
Patients with non-metastatic Castration-Resistant Prostate Cancer
Q3 2017
Otonomy Inc.
Results from phase 3 trial of OTIVIDEX (AVERTS-1)
Ménière’s Disease
2H 2017
Seres Therapeutics, Inc.
Data readout from Phase 1b study of SER-287
mild-to-moderate ulcerative colitis
2H 2017
Seres Therapeutics, Inc.
Data readout from Phase 1b study of SER-262
primary C. difficile infection
2H 2017
AstraZeneca PLC
AZN.L, AZN
Results from 2nd phase III trial of Tralokinumab (STRATOS 2)
severe asthma